Patents by Inventor Jon D. Levine
Jon D. Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10167295Abstract: Provided herein, inter alia, are methods and compositions for achieving an analgesic effect in subjects in need thereof.Type: GrantFiled: September 11, 2015Date of Patent: January 1, 2019Assignee: The Regents of the University of CaliforniaInventors: Jon D. Levine, Alejandra Gallardo-Godoy
-
Patent number: 9376423Abstract: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.Type: GrantFiled: July 1, 2014Date of Patent: June 28, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Robert Owen Messing, Michael A. Pleiss, Jon D. Levine
-
Publication number: 20160068541Abstract: Provided herein, inter alia, are methods and compositions for achieving an analgesic effect in subjects in need thereof.Type: ApplicationFiled: September 11, 2015Publication date: March 10, 2016Inventors: Jon D. Levine, Alejandra Gallardo-Godoy
-
Publication number: 20150005349Abstract: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.Type: ApplicationFiled: July 1, 2014Publication date: January 1, 2015Inventors: Robert Owen Messing, Michael A. Pleiss, Jon D. Levine
-
Publication number: 20040180916Abstract: Methods and compositions for treating, managing or ameliorating pain in a subject (preferably, a mammal, and more preferably, a human) comprising administration of a centrally acting (i.e., crosses the blood brain barrier) agonist of a &kgr;-opioid receptor and a centrally acting opioid antagonist such that the analgesia achieved by this administration is greater than with administration of either the &kgr;-opioid receptor agonist or the opioid antagonist alone. Preferably the &kgr;-opioid receptor is nalbuphine or a salt or prodrug of nalbuphine and the opioid antagonist is naloxone or a salt or prodrug of naloxone. Preferred methods of administration include mucosal (e.g. intranasal or pulmonary) and intravenous. Other &kgr;-opioid receptors include pentazocine and butorphanol.Type: ApplicationFiled: December 12, 2003Publication date: September 16, 2004Applicant: The Regents of the University of CaliforniaInventor: Jon D. Levine
-
Publication number: 20040067886Abstract: The role of the E isozyme of protein kinase C (“PKC&egr;”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC&egr;, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC&egr; and PKC&egr;-independent analgesic agent are disclosed.Type: ApplicationFiled: October 1, 2003Publication date: April 8, 2004Applicant: Regents of the University of CaliforniaInventors: Robert O. Messing, Jon D. Levine
-
Patent number: 6686334Abstract: The role of the &egr; isozyme of protein kinase C (“PKC&egr;”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC&egr;, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC&egr; and PKC&egr;-independent analgesic agent are disclosed.Type: GrantFiled: January 4, 2002Date of Patent: February 3, 2004Assignee: Regents of the University of CaliforniaInventors: Robert O. Messing, Jon D. Levine
-
Publication number: 20030207905Abstract: Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself).Type: ApplicationFiled: June 9, 2003Publication date: November 6, 2003Applicant: The Regents of the University of CaliforniaInventor: Jon D. Levine
-
Publication number: 20030149066Abstract: Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself).Type: ApplicationFiled: February 6, 2003Publication date: August 7, 2003Applicant: The Regents of the University of CaliforniaInventor: Jon D. Levine
-
Publication number: 20030096832Abstract: Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself).Type: ApplicationFiled: December 20, 2002Publication date: May 22, 2003Applicant: Regents of the University of CaliforniaInventor: Jon D. Levine
-
Patent number: 6525062Abstract: Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself). Treatment of both inflammatory and neuropathic pain can be achieved; side effects common with &mgr;-opioids such as morphine were not observed.Type: GrantFiled: June 8, 2001Date of Patent: February 25, 2003Assignee: The Regents of the University of CaliforniaInventor: Jon D. Levine
-
Publication number: 20020151465Abstract: The role of the &egr; isozyme of protein kinase C (“PKC&egr;”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC&egr;, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC&egr; and PKC&egr;-independent analgesic agent are disclosed.Type: ApplicationFiled: January 4, 2002Publication date: October 17, 2002Inventors: Robert O. Messing, Jon D. Levine
-
Patent number: 6376467Abstract: The role of the &egr; isozyme of protein kinase C (“PKC&egr;”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC&egr;, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC&egr; and PKC&egr;-independent analgesic agent are disclosed.Type: GrantFiled: July 6, 1999Date of Patent: April 23, 2002Assignee: The Regents of the University of CaliforniaInventors: Robert O. Messing, Jon D. Levine
-
Publication number: 20020016331Abstract: Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself).Type: ApplicationFiled: June 8, 2001Publication date: February 7, 2002Inventor: Jon D. Levine
-
Patent number: 4908387Abstract: A method of treating inflammation and joint deterioration in mammals which comprises administering a therapeutically effective amount of a selective beta.sub.2 adrenergic receptor antagonist. The method is particularly useful for the treatment of rheumatoid arthritis in humans.Type: GrantFiled: June 6, 1988Date of Patent: March 13, 1990Assignee: The Regents of the University of CaliforniaInventors: Jon D. Levine, Allan I. Basebaum